

Synthesis, Analysis of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Metal Complex

Vijendra Yadav¹, Jinendra Singh Chauhan², Brijesh Singh³

¹AISECT University, Bhopal, M.P., India

²BPL Govt. College Mhow, indore, M.P., India

³AISECT University, Bhopal, M.P., India

Vijendra.yad@gmail.com, c.jinendra@yahoo.in, vision.bsin@yahoo.com,

Abstract

In the present investigation synthesized new noble ligand (organic compound) 1 - {3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone derived from hydrazine and aceto-acetic ester. The 1 - {3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone consist pyrazole and imidazole nitrogen derivatives, the 'N' atom and the oxygen atom of 'S' bonded with the metal Fe(III), Cu(II) and Re(II) to form complex. The structure was confirmed by using elemental analysis, UV-VIS, mass spectrometry, and NMR spectroscopy. This work covers results concerning the complexing properties of the new ligand towards Fe (III), Cu(II) and Re(II) ions. The formation of non-covalent complexes of 1:2 stoichiometry with the Fe (III), Cu(II) and Re(II) ions analysis have been confirmed by H-NMR, ¹³CNMR and mass spectrometry.

Keywords: Pyrazol, imidazole, derivative, metal ion complexes; H-NMR, ¹³C-NMR

Introduction

The chemistry of metal complexes with ligands those containing oxygen and nitrogen as donor atoms have to attract for the research. So many organic ligands are known to coordinate to metal atom in two ways 1. Metal to ligand electron pair donation and 2. Ligand to metal donation of electrons, with under the different reaction conditions¹.

The drug (organic ligand) transition metal complexes of Manganese, cobalt, nickel, copper, and zinc are life-essential metallic elements and exhibit greater biological activity when associated with certain metal protein complexes²⁻⁵, participating in oxygen transport, electronic transfer reactions, or the storage of ions⁶⁻⁷. Mn (II), Co (II), Ni (II), Cu (II), and Zn (II) complexes of the 4-chloro-2-{(E)-[(4-phenyl)imino] methyl}phenol, has been synthesized⁸⁻⁹. The new Mn (II), Co (III), Ni (II), Cu (II), and Zn (II) complexes of the 4-chloro-2-{(E)-[(4-henyl) imino] methyl}phenol has been investigated and is now reported⁸. Evaluation results and revealed that the metal complexes are given six coordinated octahedral geometry, exhibited higher activity than the free other ligand¹⁰⁻¹¹⁻¹².

Similarly the polymeric ligands also coordinate with d-block transition metal complexes has been synthesized and reported, which are good to their high thermal stability and enormous pharmacological activity along with potential applications as functional materials¹⁶. Owing to the high thermal stability of the polymeric ligand, they specific applications such as in waste water treatment, metal recovery, protective coatings, thermally stable materials, water disinfectants, antifouling paints, antimicrobial and surgical materials, gels and ointments for medical uses, and biological activity¹³⁻¹⁴.

The polymers/copolymers/ tertiary polymeric material showing characteristics of various types of ligand with transition metal ions¹⁵⁻²⁰. The chemical properties of benzothiazole based compounds have been investigated in several research fields in polymer field because of their high thermal stability and pharmacological activity²¹⁻²², the organic chelate ring dramatically increasing the certain biological properties such as antibacterial²², antiviral²³, anti-fungal²⁴ and anti-tubercular²⁶ activities. These activities are probably due to the presence of the -N=C-S, N=N, C=S group present in the organic ligand²⁷.

The transition metal complexes of thiosemicarbazones ligand became largely appealing because of their broad profile of pharmacological activity that provides a diverse variety of compounds with different activities²⁸⁻³⁰. Some of the detected biological activities of the thiosemicarbazones and their complexes with transition metal ions are antibacterial, antifungal, antiarthritic, antimalarial, antitumor, antiviral and anti-HIV activities³¹⁻³⁵.

Thiosemicarbazone derivatives containing a 4-acyl-2-pyrazolin-5- one given an important class of organic compounds because of their structural chemistry and biological activities³⁶. In the field of anticancer research, the pyrazolones exhibited promising antiproliferative activity against human myelogenous leukaemia HL-608³⁷.

The co-ordinating property of the 4-amino-2,3-dimethyl-1-phenyl- 3-pyrazolin-5-one ligand has been modified to give a flexible ligand system, formed by condensation with a variety of reagents such as aldehydes, ketones³⁸⁻⁴⁰, thio-semicarbazides and carbazides, etc.⁴¹⁻⁴⁴.

All these study inspire us for this research, therefore; we are going to prepared new organic drug which has nitrogen, sulfur and other coordinating groups, which chelating the Fe, Cu, and Re metal ions and given different colours and specific properties.

Experiment

Synthesis of ligand

In this preparation we are using AR grade chemicals, for this synthesis 25 ml of methyl-acetoethyl-acetate mix with the 20 ml of hydrazine hydrogen chloride in to the round bottom flask then the exothermic reaction is take place at room temperature (32⁰C), and it produced compound 4-Ethoxy-4-hydrazino-butan-2-one with 12.2 gm. of yield.

After some time compound 4-Ethoxy-4-hydrazino-butan-2-one treated with the 4-imethylamino-3-hydroxymethyl-benzenesulfonic acid to given good yield 10.3 gm. of 3-(4-(3-(3-Acetyl-3H-pyrazol-4-yl)oxymethyl)-benzenesulfonic acid than it reacted with imidazole to give final product of yellow collared 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-yl)methanesulfonyl]-benzyloxy}-4H-pyrazol-4-yl}-ethanone at 140⁰C with the gentle heating up to 5 hr.'s. and recover 12.32 gm.

Yield of drug, mechanism given in scheme and the structure which given for the drug according to spectra as follows:




Figure 2.1: Structure of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone

Synthesis of metal complexes

Ethanol solution of prepared ligand (0.02 mol) and Ethanol solution of corresponding metal salts (0.02 mol) (MX_2 , where M= the Fe (III), Cu(II) and Re(IV) metal ions $X=SO_4^- / Cl^- / Acetate / NO_3^-$) were mixed together with constant stirring in acidic media. The mixture was refluxed for 3 h at 85 °C. On cooling colored solid metal complexes were precipitated out. The products were filtered, washed with petroleum ether, than we get recrystallized complex.




Figure 2.2: Structure of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone metal complex

Instrumentation

Infrared spectra of the ligand and its complexes were carried out by using KBr pellets in the range 4000-400 cm^{-1} on **Bucker model** of IR instrument. The electronic absorption was carried out by Shimadzu UV-1601 using alcohol as solvent. The Mass spectra were recorded by ESI technique on **VG AUTOSPEC** mass spectrometer instrument with **GLC**. The 1-H spectra were recorded on **Varian Gemini Unity** Spectrometer by employing TMS as internal standard, with KCl.

All the analysis done at SIRT, Bhopal and the Mass spectra analyzed at RGPV, Bhopal Pharmacy department.

1.3.0. Drug yellow coloured 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone: Elemental analysis data for $C_{17}H_{19}N_5O_4S$ found: C 49.09%; H, 4.30%; N- 17.89% calculated: C, 49.10%; H, 4.39%; N, 17.68%. FT-IR (KBr, disc cm^{-1}) 3423.2 ν (O-H), 1600.6, 1220.3 ν (C-O), 703.7 ν (H₂O), 534.8 ν (H-N), 491.7 ν (N-N). UV-Vis λ_{max} (nm) at λ_{max} (nm) 223.4, 270.2 and 358 nm. 1H NMR): δ 7.50, 2.0(-OH), 3.23(C=O), 4 (-NH₂), 7.18–7.39 (m, 7ArH); ^{13}C NMR): COCH₃ 206 164–165(-NH₂), 162(N=N),193(-COCH₃),129 (O=(S)=O), 125(C-O),138.2(-C₆H₅). And the mass spectrum at the 100% abundance is 391 eg. The mass of compound is 391 and 389.3au along with the m+2 and M-2 degradation.

1.3.1. Iron (III) Complex: Yield: 65.03%, 0.1388 g, colour: grey, m.p > 380°C, and molar conductance 18 $\Omega cm^2 mol^{-1}$. Elemental analysis data for $C_{17}H_{19}Fe(III)N_5O_4S$ found: C, 52.88%; H, 3.13%; N, 4.92% calculated: C, 52.74%; H, 4.50%; N, 4.76%. FT-IR (KBr, disc cm^{-1}) 3429.0 ν (O-H), 1601. 1215.7 ν (C-O), 701.0 ν (H₂O), 532.6 ν (Fe-N), 491.1 ν (Fe-O). 1H NMR): δ 7.50, 2.0(-OH), 3.23(C=O), 4 (-NH₂), 7.18–7.39 (m, 7ArH); ^{13}C NMR): COCH₃ 206 164–165(-NH₂), 162(N=N),193(-COCH₃),129 (O=(S)=O), 125(C-O),138.2(-C₆H₅).UV-Vis λ_{max} (nm) 221.4, 251.8, and 342.1. And the mass of complex is 838.3au. the structure as follows:




Figure 2.3: Structure of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Iron (III) complex

1.3.2. Copper (II) Complex: Yield: 61.05%, 0.2362 g, colour: red brown, m.p > 392°C, and molar conductance 22 $\Omega cm^2 mol^{-1}$. Elemental analysis data for $C_{17}H_{19}Cu(II)N_5O_4S$ found: C, 52.66%; H, 3.40%; N, 4.75% calculated: C, 52.70%; H, 3.38%; N, 4.73%. FT-IR (KBr, disc cm^{-1}) 3420.7 ν (O-H), 1595., 1214.8 ν (C-O), 697.9 ν (H₂O), 527.4 ν (Cu-N), 489.2 ν (Cu-O). UV-Vis λ_{max} (nm) 245.2, 315.1 and 422.9. 1HNMR (ppm d₆-DMSO, 400 MHz): δ 7.50, 2 7.12–7.15 (m, 7ArH); ^{13}C NMR (ppm d₆-DMSO): 124–118.32(C-O). And the mass of complex through mass spectra analysis 846.58 au.




Figure 2.4: Structure of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Copper (II) complex

1.3.3. Re (II) Complex: Yield: 73.91%, 0.2672 g, colour: brown, m.p > 394°C, and molar conductance $24 \text{ Ohm}^{-1} \text{ cm}^2 \text{ mol}^{-1}$. Elemental analysis data for $\text{C}_{17}\text{H}_{19}\text{Re (II)}\text{N}_5\text{O}_4\text{S}$ found: C, 52.41%; H, 3.34%; N, 4.72% calculated: C, 52.47%; H, 3.39%; N, 4.69%. FT-IR (KBr, disc cm^{-1}) 3455.6 $\nu(\text{O-H})$, 1599.7, 1213.9 $\nu(\text{C-O})$, 695.8 $\nu(\text{H}_2\text{O})$, 536.1 $\nu(\text{Re-N})$, 490.8 $\nu(\text{Re-O})$. $^1\text{H NMR}$: δ 7.50, 2.0(-OH), 3.23(C=O), 4 (-NH₂), 7.18–7.39 (m, 7ArH); $^{13}\text{C NMR}$: COCH₃ 206 164–165(-NH₂), 162(N=N), 193(-COCH₃), 129 (O=(S)=O), 125(C-O), 138.2(-C₆H₅). UV-Vis λ_{max} (nm) 243.1, 267.1 and 345.5. According to the mass spectra the mass of metal-drug complex is 968.21 au.






Figure 2.5: Structure of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Re (II) complex

ChemNMR H-1 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough




Protocol of the H-1 NMR Prediction:


Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
NH	2.0	2.00	amine
NH2	2.0	2.00	amine
CH3	2.09	0.86	methyl
CH2	2.84	1.23	1 alpha -C(=O)C
		1.37	methylene
		1.12	1 alpha -C(=O)-C
		0.13	1 beta -O-C
CH	4.20	0.22	1 beta -N
		1.50	methine
		1.35	1 alpha -O-C
		1.13	1 alpha -N
		0.22	1 beta -C=O
CH3	1.11	0.86	methyl
		0.25	1 beta -O-C
CH2	3.41	1.37	methylene
		0.00	1 alpha -C
		2.04	1 alpha -O-C

Figure 2.6: ¹H-NMR of 4-Ethoxy-4-hydrazino-butan-2-one

ChemNMR H-1 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough




Protocol of the H-1 NMR Prediction:


Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
CH	7.47	7.26	1-benzene
		0.28	1 -S(=O)(=O)-R
		-0.07	1 -C-O
CH	7.86	7.26	1-benzene
		0.67	1 -S(=O)(=O)-R
		-0.07	1 -C-O
CH	7.86	7.26	1-benzene
		0.67	1 -S(=O)(=O)-R
		-0.07	1 -C-O
CH	7.2	7.26	1-benzene
		?	1 -S(=O)(=O)-R
		-0.07	1 -C-O
OH	2.0	2.00	-> 1 increment(s) not found alcohol
CH2	4.79	1.37	methylene
		1.22	1 alpha -1:C*C*C*C*C*C*1
		2.20	1 alpha -O
		2.20	1 alpha -O
CH	7.50	7.50	alimine
		1.50	methine
CH	2.4	0.86	1 alpha -C=O
		?	2 unknown alpha substituent(s)
		-> 2 increment(s) not found	
CH3	2.09	0.86	methyl
		1.23	1 alpha -C(=O)C

Figure 2.7: ¹H-NMR 3-(4-acetyl-4H-pyrazol-3-yloxymethyl)-benzene sulphonic acid

ChemNMR H-1 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough




Protocol of the H-1 NMR Prediction:


Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
CH3	2.09	0.86	methyl
		1.23	1 alpha -C(=O)C
CH	2.4	1.50	methine
		0.86	1 alpha -C=O
		?	2 unknown alpha substituent(s)
			-> 2 increment(s) not found
CH	7.50	7.50	aldimine
CH2	4.79	1.37	methylene
		1.22	1 alpha -1:C*C*C*C*C*C*1
		2.20	1 alpha -O
CH	6.67	7.26	1-benzene
		-0.07	1 -C-O
		-0.80	1 -N
		0.28	1 -S(=O) (=O) -R
CH	7.61	7.26	1-benzene
		-0.07	1 -C-O
		-0.25	1 -N
		0.67	1 -S(=O) (=O) -R
CH	7.61	7.26	1-benzene
		-0.07	1 -C-O
		-0.25	1 -N
CH2	3.5	0.67	1 -S(=O) (=O) -R
		1.37	methylene
		2.08	1 alpha -S(=O) (=O)
		?	1 unknown alpha substituent(s)
			-> 1 increment(s) not found
CH	7.50	7.50	aldimine
CH	3.2	1.50	methine
		1.73	1 alpha -O
		?	2 unknown alpha substituent(s)
			-> 2 increment(s) not found
OH	2.0	2.00	alcohol
NH2	4.0	4.00	aromatic C-NH

Figure 2.8: ¹H-NMR 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone

ChemNMR C-13 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough



Protocol of the C-13 NMR Prediction:

Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
C	206.0	193.0	1-carbonyl
CH3	16.3	13.3	2 -C aliphatic
CH	163.7	160.8	1 alpha -C(=O) -C 2 gamma -C=N 1 gamma -C=O 1 delta -C
C	89.6	86.6	1 -C 1 -R from N-imine aliphatic
CH	163.7	160.8	2 alpha -C(=O) -C 1 alpha -C(=O) -C 1 beta -C 1 gamma -C steric corrections gamma corrections
CH2	70.4	67.4	1 -C 1 -R from N-imine aliphatic
C	138.2	135.2	1 alpha -C(=O) -C 1 beta -C 1 gamma -C steric corrections gamma corrections
CH	132.6	129.6	1 -benzene 1 -C(=O) -C 1 -S(=O) (=O)
CH	129.4	126.4	1 -benzene 1 -C(=O) -C 1 -S(=O) (=O)
CH	125.6	122.6	1 -benzene 1 -C(=O) -C 1 -S(=O) (=O)
C	138.4	135.4	1 -benzene 1 -C(=O) -C 1 -S(=O) (=O)
CH	125.6	122.6	1 -benzene 1 -C(=O) -C 1 -S(=O) (=O)
CH	163	160	1 -imine 1 unknown substituent(s) 1 -C from N-imine
C	164	161	1 -imine 1 -C 1 unknown substituent(s) 1 -R from N-imine
CH2	40.5	37.5	1 -C 1 -R from N-imine 1 unknown substituent(s) 1 increment(s) not found aliphatic
			1 alpha -C=N 1 alpha -C(=O) -C 1 beta -S(=O) =O 1 gamma -C(=O) -C steric corrections gamma corrections

Figure 2.9: ¹³C-NMR 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone




Figure 2.10: IR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone




Figure 2.11: UV-VIS Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone




Figure 2.12: IR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Iron (II) complex




Figure 2.13: UV-VIS Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Iron (II) complex




Figure 2.14: IR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Cooper (II) complex




Figure 2.15: UV-VIS Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Cooper (II) complex




Figure 2.16: IR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Re (II) complex






Figure 2.17: UV-VIS Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Re (II) complex

ChemNMR H-1 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough



Protocol of the H-1 NMR Prediction:

Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
CH3	2.09	1:0:0	methyl
CH	2.4	1:0:0	alpha -C(=O)C
CH	7.50	1:0:0	unknown alpha substituent (s)
CH2	4.79	1:0:0	increment(s) not found
CH	7.57	1:0:0	aldehyde
CH	7.64	1:0:0	alpha -C(=O)C
CH	7.64	1:0:0	alpha -C(=O)C
CH2	2.8	1:0:0	methylene -C(=O)C
CH	7.50	1:0:0	unknown alpha substituent (s)
CH	7.50	1:0:0	increment(s) not found
NH2+	8.0	1:0:0	aromatic C-NH+
CH3	2.09	1:0:0	methyl
CH	2.4	1:0:0	alpha -C(=O)C
CH	7.50	1:0:0	unknown alpha substituent (s)
CH2	4.79	1:0:0	increment(s) not found
CH	7.57	1:0:0	aldehyde
CH	7.64	1:0:0	alpha -C(=O)C
CH	7.64	1:0:0	alpha -C(=O)C
CH2	2.8	1:0:0	methylene -C(=O)C
CH	7.50	1:0:0	unknown alpha substituent (s)
CH	7.50	1:0:0	increment(s) not found
OH	2.0	1:0:0	alcohol
NH2+	8.0	1:0:0	aromatic C-NH+

Figure 2.18: ¹H-NMR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Fe (II) complex

ChemNMR C-13 Estimation






Figure 2.19: ¹³C-NMR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Fe (II) complex

ChemNMR H-1 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough




Protocol of the H-1 NMR Prediction:

Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
CH3	2.09	10.000000000000000	methyl
CH	2.4	11.000000000000000	1 alpha -C(=O)C
CH	7.50	17.000000000000000	methine
CH2	4.79	17.000000000000000	1 alpha -C=O
CH	6.61	17.000000000000000	2 unknown alpha substituent(s)
CH	7.33	17.000000000000000	1 alpha -C(=O)C
CH	7.33	17.000000000000000	2 unknown alpha substituent(s)
OH	2.8	17.000000000000000	aldehyde
CH2	2.8	17.000000000000000	1 alpha -C(=O)C
CH	7.50	17.000000000000000	2 unknown alpha substituent(s)
CH	3.20	17.000000000000000	1 alpha -C(=O)C
OH	4.0	17.000000000000000	aldehyde
CH2	4.0	17.000000000000000	1 alpha -C(=O)C
OH	4.0	17.000000000000000	aldehyde
CH2	4.0	17.000000000000000	1 alpha -C(=O)C
CH	7.50	17.000000000000000	2 unknown alpha substituent(s)
CH	4.79	17.000000000000000	1 alpha -C(=O)C
CH	6.61	17.000000000000000	2 unknown alpha substituent(s)
CH	7.33	17.000000000000000	1 alpha -C(=O)C
CH	7.33	17.000000000000000	2 unknown alpha substituent(s)
CH2	2.8	17.000000000000000	aldehyde
CH	7.50	17.000000000000000	2 unknown alpha substituent(s)
CH	3.20	17.000000000000000	1 alpha -C(=O)C
OH	4.0	17.000000000000000	aldehyde
NH2	4.0	17.000000000000000	aldehyde
OH	4.0	17.000000000000000	aldehyde

Figure 2.20: ¹H-NMR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Cu (II) complex

ChemNMR C-13 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough






Figure 2.21: ¹³C-NMR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Cu (II) complex

ChemNMR H-1 Estimation



Estimation Quality: blue = good, magenta = medium, red = rough



Protocol of the H-1 NMR Prediction:

Node	Shift	Base + Inc.	Comment (ppm rel. to TMS)
CH3	2.09	0.000	methyl
CH	2.4	0.000	1 alpha -C(=O)C
CH	7.50	7.000	1 alpha -C=O
CH2	4.79	4.000	2 unknown alpha substituent(s)
CH	6.61	6.000	1 alpha -O
CH	7.33	7.000	1 benzene -O
CH	7.33	7.000	1 benzene -O
CH2	2.8	2.000	1 alpha -O
CH	7.50	7.000	1 alpha -O
CH	3.2	3.000	1 alpha -O
OH	2.0	2.000	1 unknown alpha substituent(s)
CH3	4.0	4.000	1 alpha -O
CH	2.4	2.000	1 alpha -O
CH	7.50	7.000	1 alpha -O
CH2	4.79	4.000	2 unknown alpha substituent(s)
CH	6.61	6.000	1 alpha -O
CH	7.33	7.000	1 benzene -O
CH	7.33	7.000	1 benzene -O
CH2	2.8	2.000	1 alpha -O
CH	7.50	7.000	1 alpha -O
CH	3.2	3.000	1 alpha -O
OH	2.0	2.000	1 unknown alpha substituent(s)
NH2	4.0	4.000	1 aromatic C-NH

Figure 2.22: ¹H-NMR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Re (II) complex

ChemNMR C-13 Estimation




Figure 2.23: ^{13}C -NMR Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Re (II) complex




Figure 2.24: Mass Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone




Figure 2.25: Mass Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Iron (III)




Figure 2.26: Mass Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Cooper (III)




Figure 2.27: Mass Spectra of 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone Re (III)

Results and Discussion

The 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand in this study synthesized using the reflux method. In this research, however,

the ligand was prepared at 140°C temperature which afforded a higher yield of 12.2 gm. The ligand and metal (II) complexes of the ligand are new and it reported first time. The 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand is soluble in hot ethanol and solvents such as DMF and DMSO.

The ligand yellow coloured and its metal (II) complexes are also coloured solids which are stable in air, the complexes were insoluble in common organic solvents such as methanol, dichloromethane, ethanol, and acetone but soluble in DMSO and DMF.

The melting points of the complexes were higher than that of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand its Indicating that the complexes are more stable than the ligand. The chemical equations showing the preparation of its ligand and its metal (II) complexes scheme 2.1 and scheme 2.2.

Electronic Spectral Analysis

The electronic absorption was carried out by the instrument Shimadzu -1601 using alcohol as solvent The electronic spectral data of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand and its metal complexes are given in the experimental part of unit. The 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand showing three bands at λ_{\max} (nm) 223.4, 270.2 and 358 nm. These bands at 223.4 nm is due to the $\pi-\pi^*$ transition in benzene, the band appearing at 270.2 nm is assignable to $n-\pi^*$ transition of nonbonding electrons present on the $-\text{NH}_2$, and the band at 358.1nm is due to $n-\pi^*$ transition of the phenolic group⁴⁶⁻⁴⁷. The UV-Vis spectra of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone metal complexes are presented in the similar absorption spectra as the ligand, but it have either a blue shift or red shift.

The bands of electronic spectrum for the Fe (III) complex goes to shorter wavelength and gave three bands similar to ligand at λ_{\max} (nm) 221.4, 251.8, and 342.1. The band at 221.4nm and 251.8nm was due to intra-ligand transition, and the band at 342.1nm was as a result of d-d low-spin transition which revealed that the complex have octahedral geometry around Fe (III) ion 48-49. In case of Re (II) complex, three bands were determined at λ_{\max} (nm) 243.1, 267.1 and 345.5. This was a shift towards longer wavelength with respect to the spectrum of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand. (e band at 267.1 nm. It due to intra-ligand transition, and the band at 345.5nm was as a result of d-d transition for the range for octahedral configuration as reported in many octahedral Re (II) complexes⁵⁰⁻⁵². The electronic spectrum of Cu (II) complex showed three bands at λ_{\max} (nm) 245.2, 315.1 and 422.9nm. The band at 245.2nm founds probably due to intra-ligand transition, while the band at 422.9 nm was due to charge transfer, the observed band at 422.9nm found as a result of d-d transition which favors the tetrahedral environment in Cu (II) complexes, the copper (II) complex spectrum⁵²⁻⁵⁶ also the absence band below 10,000 cm^{-1} which is possibility of a tetrahedral environment in Cu(II) complexes⁵⁷⁻⁵⁹. It can also count that a shift in the spectral bands of the complexes with respect to the spectrum of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone is shifted towards bathochromic shift.

FT-IR Spectral Analysis of complex

Infrared spectra of the ligand and its complexes were carried out by using KBr pellets in the range of 4000-400 cm^{-1} with the Bucker model of IR instrument, the binding mode of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand and metal ion combination in complexes was determined by comparing the FT-IR spectrum of the free ligand with the spectra of the metal complexes.

The stretching frequency for the ligand and the metal complexes were analyzed and we get the frequency for Fe (III) complex at IR (KBr, disc cm^{-1}) 3429.0 ν (O-H), 1601. 1215.7 ν (C-O), 701.0 ν (H₂O), 532.6 ν (Fe-N), 491.1 ν (Fe-O), similarly for Cu(II) and Re(II) complex we found the frequencies at %. FT-IR (KBr, disc cm^{-1}) 3420.7 ν (O-H), 1595., 1214.8 ν (C-O), 697.9 ν (H₂O), 527.4 ν (Cu-N), 489.2 ν (Cu-O) and for Re(II) we get FT-IR (KBr, disc cm^{-1}) 3455.6 ν (O-H), 1599.7, 1213.9 ν (C-O), 695.8 ν (H₂O), 536.1 ν (Re-N), 490.8 ν (Re-O) in which stretching 1601 cm^{-1} , 1595 cm^{-1} and 1599.7 cm^{-1} occurs for metal-NH₂ bonding in complexes, respectively. This indicated coordination of ligand through the nitrogen⁶⁰. Moreover, the appearance of weak bands in the region 532.6 ν (Fe-N), 491.1 ν (Fe-O) ν (H₂O), 527.4 ν (Cu-N), 489.2 ν (Cu-O) 695.8 ν (H₂O), 536.1 ν (Re-N), 490.8 ν (Re-O) found for ν (M-N) and ν (M-O), respectively 61 further confirmed complexation⁶¹⁻⁶². This showed that the ligand coordinated to the metal through the "N" and "O" atoms.

The FT-IR spectra of the complexes also showed strong bands in the 3420.3–3455.6 cm^{-1} regions, suggested that the presence of coordinated/lattice water in complexes. This is also confirmed by the non-ligand band in the 695.8–701 cm^{-1} regions⁶³⁻⁶⁴.

Elemental Analysis

The micro-analysis of data revealed that all the metal-ligand complexes are mononuclear where two moles of the ligand were coordinated to the central metal atom. Therefore, it suggested that the metal to ligand ratio in the complex was 1: 2 and the general formula for the complexes as $[\text{M}(\text{L})_2(\text{H}_2\text{O})_2]$ where M=Fe (III), Cu (II), and Re (II)⁶⁵. The theoretical (calculated) values were found to be in good agreement with the experimental values.

NMR Spectra Analysis.

The ¹H and ¹³C NMR spectra of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone ligand and its Fe (III), Cu (II) and Re (II) complexes were recorded in DMSO. The ¹H NMR spectrum of the 1-{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone showed a singlet peak at δ 7.50 ppm corresponding to proton 64-65, it indicate that the -{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone are formed during the reaction. Observation of a peak at δ 162.82 ppm in the ¹³C NMR spectrum was further proof that the ligand was successfully synthesized⁶⁶.

The 1 -{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone shifted up-field in the ¹H NMR spectra of the Cu (II) and Re (II) complexes (δ 7.50 ppm). The up field shifting of amino proton in Cu (II) and Re (II) complexes was showing the discharge of electronic cloud towards the Cu (II) and Re(II) ions which is the indication of coordination through the amine nitrogen to the metallic ion⁶⁷. This is confirmation of deprotonation of the group and coordination of the negatively charged oxygen species to the metal cations. This observation also given proof of metal complexes and explains the non-electrolytic

behavior of the complexes. The ^{13}C NMR peaks for the carbon atom and imidazole group carbons are coordinate to organic ligand were we observed shift at δ 165 ppm and 162 ppm, in the spectra of the Cu (II) complex, a 2 ppm up field shift from free organic ligand, due to coordination bonding⁶⁸⁻⁶⁹.

The data of ^1H NMR and ^{13}C NMR; spectroscopy confirmation the monobasic dentate nature of the organic ligand, it already observed by the FT-IR spectral studies.

Mass Spectrum analysis

The mass spectrum of the organic ligand showing a molecular ion peak at m/z 391 ($M+2$) which is consistent with the molecular weight of the ligand 389.3, and the m/z for Fe(III), Cu(II) and for Re(II) complexes obtained at 838.3, 846.58 and 968.3 respectively which is the confirmation of complex synthesis⁷⁰.

Conclusion

In this study, the synthesis of a new macro-cyclic derivative of pyrazol and imidazol is count as the 1 -{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone where, the spectroscopic analysis of data were investigated ligand complexes with Cu(II) in DMSO and ethyl alcohol.

The Electrochemical, IR, NMR, and MS analysis have been confirmed the unexpected and possibilities of metal complex formation by a new organic ligand that is 1 -{3-[2-Amino-5-(5-hydroxy-5H-imidazol-4-ylmethanesulfonyl)-benzyloxy]-4H-pyrazol-4-yl}-ethanone. The metal ligand ratio in complex is found stable 1:2 in the solvent. Furthermore, complex is attracted to nitrogen atoms and oxygen atoms. The NMR ^1H and ^{13}C is also revealed that the complex have tetrahedral structure and it also containing the biological activity.

Mass spectra analysis confirmed the existence of complexes with ions in same oxidation state but Only in the case of ions reduction from copper (II) to copper (I) ion has been observed during experimental conditions and the obtained complex is only formed by endo-cyclic nitrogen atom from complex. The mass analyses results show that the complexes are formed stable under the conditions of applied voltage and do not undergo fragmentation with metal ion detachment. And the mass spectrum occurs for Fe(III), Cu(II) and Re(II) complexes at 838.3, 846.58 and 968.3 respectively which is the confirmation of complex synthesis.

References

1. AN-Philip Meyer, Pierre Adumeau, Jason S. Lewis, and Brian M. Zeglis . Click Chemistry and Radiochemistry: The First 10 Years. *Bioconjugate Chemistry* **2016**, 27 (12) , 2791-2807.
2. Vinod K. Tiwari, Bhuwan B. Mishra, Kunj B. Mishra, Nidhi Mishra, Anoop S. Singh, and Xi Chen . Cu-Catalyzed Click Reaction in Carbohydrate Chemistry. *Chemical Reviews* **2016**, 116 (5) , 3086-3240.
3. Warrick K. C. Lo, Gregory S. Huff, John R. Cubanski, Aaron D. W. Kennedy, C. John McAdam, David A. McMorran, Keith C. Gordon, and James D. Crowley . Comparison of Inverse and Regular 2-Pyridyl-1,2,3-triazole “Click” Complexes: Structures, Stability, Electrochemical, and Photophysical Properties. *Inorganic Chemistry* **2015**, 54 (4) , 1572-1587.
4. Asif Noor, Gregory S. Huff, Sreedhar V. Kumar, James E. M. Lewis, Brett M. Paterson, Christine Schieber, Paul S. Donnelly, Heather J. L. Brooks, Keith C. Gordon, Stephen C. Moratti, and James D. Crowley . [Re(CO)₃]⁺ Complexes of *exo*-Functionalized Tridentate “Click” Macrocycles: Synthesis, Stability, Photophysical Properties, Bioconjugation, and Antibacterial Activity. *Organometallics* **2014**, 33 (24) , 7031-7043.
5. Chung Ying Chan, Paul A. Pellegrini, Ivan Greguric, and Peter J. Barnard . Rhenium and Technetium Tricarbonyl Complexes of N-Heterocyclic Carbene Ligands. *Inorganic Chemistry* **2014**, 53 (20) , 10862-10873.
6. H. Schiff, “Mittheilungen aus dem Universitätslaboratorium in Pisa: Eine neue Reihe organischer Basen,” *Annalen der Chemie und Pharmacie*, vol. 131, no. 1, pp. 118-119, 1864.
7. B. S. Sathe, E. Jayachandran, V. A. Jagtap, and G. M. Sreenivasa, “Synthesis and antibacterial, antifungal activity of novel analogs of fluoro benzothiazole Schiff bases,” *Journal of Chemical and Pharmaceutical Sciences*, vol. 3, no. 4, pp. 216-217, 2010.
8. S. M. Sondhi, N. Singh, A. Kumar, O. Lozach, and L. Meijer, “Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/ benzoxazole derivatives and some schiff’s bases,” *Bioorganic & Medicinal Chemistry*, vol. 14, no. 11, pp. 3758–3765, 2006.
9. R. M. Mishra, S. Pandey, and R. Saxena, “Homozygous hemoglobin D with alpha thalassemia: case report,” *Open Hematology Journal*, vol. 2, pp. 1–4, 2011.
10. C. Ajit Kumar and S. N. Pandeya, “Synthesis and anticonvulsant activity (chemoshock) of schiff and mannich bases of isatin derivatives with 2-amino pyridine (mechanism of action),” *International Journal of PharmTech Research*, vol. 4, no. 2, pp. 590–598, 2012.
11. T. Aboul-Fadl, F. A.-H. Mohammed, and E. A.-S. Hassan, “Synthesis, antitubercular activity and pharmacokinetic studies of some schiff bases derived from 1- alkylisatin and isonicotinic acid hydrazide (inh),” *Archives of Pharmacal Research*, vol. 26, no. 10, pp. 778–784, 2003.
12. D. Wei, N. Li, G. Lu, and K. Yao, “Synthesis, catalytic and biological activity of novel dinuclear copper complex with Schiff base,” *Science in China Series B*, vol. 49, no. 3, pp. 225–229, 2006.

13. P. G. Avaji, C. H. Vinod Kumar, S. A. Patil, K. N. Shivananda, and C. Nagaraju, "Synthesis, spectral characterization, invitro microbiological evaluation and cytotoxic activities of novel macrocyclic bis hydrazone," *European Journal of Medicinal Chemistry*, vol. 44, no. 9, pp. 3552–3559, 2009.
14. Z. H. Chohan, J. L. Wardell, J. N. Low, P. R. Meehan, and G. Ferguson, "Tetraethylammonium bromo(1,3-dithiol-2-one-4,5-dithiolato)diethylstannate(1-)," *Acta Crystallographica Section C Crystal Structure Communications*, vol. 54, no. 10, 1998.
15. K. Shoaib, W. Rehman, B. Mohammad, and S. Ali, "Proteomics and bioinformatics synthesis, characterization and biological applications of transition metal complexes of [no] donor schiff bases," *Journal of Proteomics & Bioinformatics*, vol. 6, no. 7, pp. 153–157, 2013.
16. K. H. Kailas, J. P. Sheetal, P. P. Anita, and H. P. Apoorva, "Four synthesis methods of schiff base ligands and preparation of their metal complex with Ir and antimicrobial investigation," *World Journal of Pharmacy and Pharmaceutical Sciences*, vol. 5, no. 2, pp. 1055–1063, 2016.
17. M. R. S. Zaidan, A. Noor Rain, A. R. Badrul, A. Adlin, A. Norazah, and I. Zakiah, "In vitro screening of five local medicinal plants for antibacterial activity using disc diffusion method antibacterial activity using disc diffusion method," *Tropical Biomedicine*, vol. 22, no. 2, pp. 165–170, 2006.
18. P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Tenover, *Manual of Clinical Microbiology*, ASM, Washington, DC, USA, 1995.
19. T.-J. Feng, "4-Chloro-2-[(E)-(4-fluorophenyl)iminomethyl] phenol," *Acta Crystallographica Section E Structure Reports Online*, vol. 70, no. 1, p. 42, 2014.
20. W. J. Geary, "The use of conductivity measurements in organic solvents for the characterisation of coordination compounds," *Coordination Chemistry Reviews*, vol. 7, no. 1, pp. 81–122, 1971.
21. L. Chen, K. (ompson, N. Bridson, and L. Chenvol, "Dinuclear copper(II) and copper (I) complexes of tetradentate (N4)thio-diazine ligands; synthetic, structural, magnetic and electrochemical studies: in situ oxidation of copper(I) complexes to produce dinuclear hydroxo-bridged copper(II) complexes," *Inorganica Chimica Acta*, vol. 214, pp. 67–76, 1993.
22. A. M. Shaker, L. A. E. Nassr, M. S. S. Adam, and I. M. A. Mohamed, "Hydrophilicity and acid hydrolysis of water-soluble antibacterial iron(II) Schiff base complexes in binary aqueous solvents," *Russian Journal of General Chemistry*, vol. 83, no. 12, pp. 2460–2464, 2013.
23. D. M. Boghaei, E. Askarizadeh, and A. Bezaatpour, "Synthesis, characterization, spectroscopic and thermodynamic studies of charge transfer interaction of a new water-soluble cobalt (II) Schiff base complex with imidazole derivatives," *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, vol. 69, no. 2, pp. 624–628, 2008.
24. I. Bertini, *Inorganic and Bio-Inorganic Chemistry*, EOLSS, Oxford, UK, 2009.
25. A. A. Abou-Hussein and W. Linert, "Synthesis, spectroscopic, coordination and biological activities of some organometallic complexes derived from thio-Schiff base ligands," *SpectrochimActa-Part A Mol Biomol Spectrosc*, vol. 117, 2014.
26. G. G. Mohamed, M. A. Zayed, and S. M. Abdallah, "Metal complexes of a novel Schiff base derived from sulphametrole and varelaldehyde. Synthesis, spectral, thermal

- characterization and biological activity,” *Journal of Molecular Structure*, vol. 979, no. 1–3, pp. 62–71, 2010.
27. Liberta, West. Antifungal and antitumor activity of heterocyclic thiosemicarbazones and their metal complexes: current status. *Biometals*. 1992; 5: 121–6.
 28. S. Padhye , RC Chikate , PB Sonawane, et al. Thiosemicarbazone complexes of copper(II): structural and biological studies. *Coord Chem Rev*. 1993; 123: 49–71.
 29. J G Cory, AH Cory , Rappa , et al. Inhibitors of ribonucleotide reductase Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehydethiosemicarbazones. *Biochem Pharmacol*. 1994; 48: 335–44.
 30. DS Raja , NPS Bhuvanesh, K Natarajan . Biological evaluation of a novel water soluble sulphur bridged binuclear copper(II) thiosemicarbazone complex. *Eur J Med Chem*. 2011; 46: 4584–94.
 31. ES Raper. Complexes of heterocyclic thione donors. *Coord Chem Rev*. 1985; 61: 115–84.
 32. JS Casas, MS Garci-Tasende , Maichle- Mossmer , et al. Synthesis, structure and spectroscopic properties of acetate (dimethyl)(pyridine-2-carbaldehydethiosemicarbazonato) tin(IV) acetic acid solvate, SnMe₂(PyTSC)(OAc).HOAc. Comparison of its biological activity with that of some structurally related diorganotin(IV)bis(thiosemicarbazone). *J Inorg Biochem*. 1996; 62: 41–55.
 33. EW Ainscough ,AM Brodie, WA Denny , et al. Nitrogen, sulfur and oxygen donor adducts with copper(II) complexes of antitumor 2-formylpyridine thiosemicarbazone analogs: physicochemical and cytotoxic studies. *J Inorg Biochem*. 1998; 70: 85–175.
 34. Mishra V, Pandeya SN, Pannecouque C, et al. Anti-HIV Activity of Thiosemicarbazone and Semicarbazone Derivatives of (–)-3-Menthone. *Arch Pharm*. 2002; 335: 183–6.
 35. MC Rodriguez-Arguelles, EC Lopez-Silva, J Sanmartin , et al. Copper complexes of imidazole-2-, pyrrole-2- and indol-3-carbaldehyde thiosemicarbazones: inhibitory activity against fungi and bacteria. *J Inorg Biochem*. 2005; 99: 2231–9.
 36. NC Saha , C Biswas, AGhorai , et al. Synthesis, structural characterisation and cytotoxicity of new iron(III) complexes with pyrazolyl thiosemicarbazones. *Polyhedron*. 2012; 34: 1–12.
 37. AK Rana , NR Parekh , et al. Novel synthesis and characterization of thiosemicarbazone compounds containing 4-Acyl-2-pyrazolin-5- ones. *Eur J Chem*. 2009; 6: 747–52.
 38. MF Brana , A Gradillas, AG Ovalles , et al. Synthesis and biological activity of N, N-dialkylaminoalkyl- substituted bisindolyl and diphenyl pyrazolone derivatives. *Bioorg Med Chem*. 2006; 14: 9–16.
 39. Dharmaraj, Viswanathamurthi, K Natarajan K. Ruthenium (II) complexes containing bidentate Schiff bases and their antifungal activity. *Transition Met Chem*. 2001; 26: 105–9.
 40. Raman , A Kulandaisamy , K Jeyasubramanian K. Synthesis, structural characterization, redox and antimicrobial studies of Schiff base copper(II), nickel(II), cobalt(II), manganese(II), zinc(II) and oxovanadium(II) complexes derived from benzil and 2-aminobenzyl alcohol. *Polish J Chem*. 2002; 76: 1085–94.
 41. M. S. Nair, D. Arish, and R. S. Joseyphus, “Synthesis, characterization, antifungal, antibacterial and DNA cleavage studies of some heterocyclic Schiff base metal complexes,” *Journal of Saudi Chemical Society*, vol. 16, no. 1, pp. 83–88, 2012.
 42. J. H. Aupers, Z. H. Chohan, P. J. Cox et al., “Syntheses and structures of diorgano(halo-orpseudohalo-)(1,3-dithiole-2-thione- 4,5-dithiolato)-stannates (1-), *Polyhedron*, vol. 17, no. 25-26, 1998.

43. P. W. Selwood, *Magnetochemistry*, Interscience, London, UK, 1956.
44. A. H. Chohan, A. I. Che-Ani, M. M. Tahir, N. A. G. Abdullah, N. M. Tawil, and S. N. Kamaruzzaman, "Housing and analysis of design defects: a post occupational evaluation of private housing in Malaysia," *International Journal of Physical Sciences*, vol. 6, no. 2, pp. 193–203, 2011.
45. M. Alias, H. Kassum, and C. Shakir, "Synthesis, physical characterization and biological evaluation of Schiff base Journal of Chemistry 7 M(II) complexes," *Journal of the Association of Arab Universities for Basic and Applied Sciences*, vol. 15, no. 1, pp. 28–34, 2014.
46. A. M. Shaker, L. A. E. Nassr, M. S. S. Adam, and I. M. A. Mohamed, "Hydrophilicity and acid hydrolysis of water-soluble antibacterial iron(II) Schiff base complexes in binary aqueous solvents," *Russian Journal of General Chemistry*, vol. 83, no. 12, pp. 2460–2464, 2013.
47. D. M. Boghaei, E. Askarizadeh, and A. Bezaatpour, "Synthesis, characterization, spectroscopic and thermodynamic studies of charge transfer interaction of a new water-soluble cobalt (II) Schiff base complex with imidazole derivatives," *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, vol. 69, no. 2, pp. 624–628, 2008.
48. I. Bertini, *Inorganic and Bio-Inorganic Chemistry*, EOLSS, Oxford, UK, 2009.
49. A. A. Abou-Hussein and W. Linert, "Synthesis, spectroscopic, coordination and biological activities of some organometallic complexes derived from thio-Schiff base ligands," *Spectrochim Acta-Part A Mol Biomol Spectrosc*, vol. 117, 2014.
50. A. A. El-Sherif, M. R. Shehata, M. M. Shoukry, and M. H. Barakat, "(ermodynamic investigation and mixed ligand complex formation of 1,4-Bis-(3-aminopropyl)-piperazine and biorelevant ligands," *Bioinorganic Chemistry and Applications*, vol. 2012, Article ID 984291, 10 pages, 2012.
51. G. G. Mohamed, M. A. Zayed, and S. M. Abdallah, "Metal complexes of a novel Schiff base derived from sulphametrole and varelaldehyde. Synthesis, spectral, thermal characterization and biological activity," *Journal of Molecular Structure*, vol. 979, no. 1–3, pp. 62–71, 2010.
52. M. S. Nair, D. Arish, and R. S. Joseyphus, "Synthesis, characterization, antifungal, antibacterial and DNA cleavage studies of some heterocyclic Schiff base metal complexes," *Journal of Saudi Chemical Society*, vol. 16, no. 1, pp. 83–88, 2012. [24] J. H. Aupers, Z. H. Chohan, P. J. Cox et al., "Syntheses and structures of diorgano(halo- orpseudohalo-)(1,3-dithiole-2-thione- 4,5-dithiolato)-stannates (1-), [Q][R₂SnX(dmit)] onium cation; halide orpseudohalide)," *Polyhedron*, vol. 17, no. 25- 26, 1998.
53. P. W. Selwood, *Magnetochemistry*, Interscience, London, UK, 1956.
54. A. H. Chohan, A. I. Che-Ani, M. M. Tahir, N. A. G. Abdullah, N. M. Tawil, and S. N. Kamaruzzaman, "Housing and analysis of design defects: a post occupational evaluation of private housing in Malaysia," *International Journal of Physical Sciences*, vol. 6, no. 2, pp. 193–203, 2011.
55. M. Alias, H. Kassum, and C. Shakir, "Synthesis, physical characterization and biological evaluation of Schiff base Journal of Chemistry 7 M(II) complexes," *Journal of the Association of Arab Universities for Basic and Applied Sciences*, vol. 15, no. 1, pp. 28–34, 2014.
56. J. Ferraro, "Low Frequency vibration of inorganic and coordination compound," Plenum press, New York, NY, USA, 1971.

57. K. Nakamoto, *Infrared Raman Spectra of Inorganic and Coordination Compounds*, John Wiley & Sons, New York, NY, USA, third edition, 1992.
58. J. P. Tandon, A. J. Crowe, and F. Road, "Synthesis and structural studies of TIN(II) complexes of semicarbazones and thiosemicarbazones," *Polyhedron*, vol. 5, no. 3, pp. 739–742, 1986.
59. A. M. Hammam, Z. A. Khafagi, and S. A. Ibrahim, "Synthesis and characterization of some new antimicrobial transition metal complexes with 1, 2, 4-Traizole-3-thione schiff bases," *Journal of Materials and Environmental Science*, vol. 6, no. 6, pp. 1596–1605, 2015.
60. C. I. R. Sobana, G. A. R. Gnana, and M. A. Princela, "Synthesis and characterization of bioactive transition metal complexes of Zr(IV) and (IV) using di- α -formylmethoxy bis (3-penta decenyl phenyl) methane (DFMPM) derived from Cardanol," *AJCPR*, vol. 3, no. 1, pp. 208–214, 2015.
61. B. V. Agarwala, S. Hingorani, and V. Puri, "KCL. Physicochemical studies of (o-vanillin thiosemicarbazonato)-nickel(II) chelate," *Transition Metal Chemistry*, vol. 19, pp. 25–27, 1994.
62. H. Gunther, *NMR Spectroscopy: Basic Principles, Concepts, and Applications in Chemistry*, JohnWiley & Sons, Hoboken, NJ, USA, 2nd edition, 1995.
63. B. Manjula and S. Arul, "Preparation, characterization, antimicrobial activities and DNA cleavage studies of Schiff base complexes derived from 4-amino antipyrine," *Asian Journal of Biochemical and Pharmaceutical Research*, vol. 1, pp. 168–178, 2013.
64. E. Canpolat, A. Yazici, and M. Kaya, "Studies on mononuclear chelates derived from substituted Schiff-base ligands (part 10): synthesis and characterization of a new 4-hydroxysalicylidenp- aminoacetophenoneoxime and its complexes with Co(II), Ni(II), Cu(II) and Zn(II)," *Journal of Coordination Chemistry*, vol. 60, no. 4, pp. 473–480, 2007.
65. R. A. Nyquist, *Interpreting Infrared, Raman and Nuclear Magnetic Resonance Spectra*, vol. 2, Academic Press, New York, NY, USA, 2001.
66. J. Ferraro, "Low Frequency vibration of inorganic and coordination compound," Plenum press, New York, NY, USA, 1971.
67. K. Nakamoto, *Infrared Raman Spectra of Inorganic and Coordination Compounds*, John Wiley & Sons, New York, NY, USA, (ird edition, 1992). J. P. Tandon, A. J. Crowe, and F. Road, "Synthesis and structural studies of TIN(II) complexes of semicarbazones and thiosemicarbazones," *Polyhedron*, vol. 5, no. 3, pp. 739–742, 1986.
68. A. M. Hammam, Z. A. Khafagi, and S. A. Ibrahim, "Synthesis and characterization of some new antimicrobial transition metal complexes with 1, 2, 4-Traizole-3-thione schiff bases," *Journal of Materials and Environmental Science*, vol. 6, no. 6, pp. 1596–1605, 2015.
69. C. I. R. Sobana, G. A. R. Gnana, and M. A. Princela, "Synthesis and characterization of bioactive transition metal complexes of Zr(IV) and (IV) using di- α -formylmethoxy bis (3-pentadecenyl phenyl) methane (DFMPM) derived from Cardanol," *AJCPR*, vol. 3, no. 1, pp. 208–214, 2015.
70. B. V. Agarwala, S. Hingorani, and V. Puri, "KCL. Physicochemical studies of (o-vanillin thiosemicarbazonato)-nickel(II) chelate," *Transition Metal Chemistry*, vol. 19, pp. 25–27, 1994.

IJSER